Drug shows promise for kidney cancer brain metastases in early trial

NCT ID NCT00814021

Completed Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sunitinib (a drug that blocks tumor growth and blood flow)
What this could lead to: If it works, this could offer a new treatment option for kidney cancer that has spread to the brain, potentially shrinking tumors and controlling the disease.
What could go wrong: This is a small, early-phase trial with only 21 participants, so results may not apply widely. The drug may not shrink brain tumors effectively or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer kidney cancer metastatic malignant neoplasm Neoplasm Metastasis renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER METASTATIC CANCER

Contacts and locations

Locations

Institut Claudius Regaud

Toulouse, 31052, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.